Introduction (±)-Mecamylamine is a nonselective antagonist of nicotinic acetylcholine receptors. The mechanisms underlying the pharmacological activity of this compound, the exact location and structural components of the mecamylamine binding sites at antagonist of nicotinic acetylcholine receptors have not been clearly demonstrated yet. The aim of this study was to discuss how mecamylamine inhibits muscle nicotinic acetylcholine receptors by competitive and noncompetitive mechanisms.
Introduction
(±)-Mecamylamine is a nonselective antagonist of nicotinic acetylcholine receptors. The mechanisms underlying the pharmacological activity of this compound, the exact location and structural components of the mecamylamine binding sites at antagonist of nicotinic acetylcholine receptors have not been clearly demonstrated yet. The aim of this study was to discuss how mecamylamine inhibits muscle nicotinic acetylcholine receptors by competitive and noncompetitive mechanisms.
Methods
The pharmacological properties of (±)-mecamylamine were characterised at different human muscle nicotinic acetylcholine receptors by radioligand binding assays, employing the noncompetitive antagonist 
Introduction
(±)-Mecamylamine (see structure of the enantiomers in Figure 1 ) was originally developed for the treatment of hypertension, however, new studies have demonstrated that this drug also possess antiaddictive, antidepressant and pro-cognitive properties 1, 2 . The involved acetylcholine receptor (AChR) subtypes and mechanisms underlying these pharmacologic activities have not been clearly demonstrated yet. Additional results indicate that the pharmacological and clinical activities of mecamylamine are more complex than previously thought [2] [3] [4] [5] [6] [7] [8] [9] . Previous results from our laboratory demonstrated that the mecamylamine binding sites do not overlap the sites for tricyclic antidepressants in the hα4β2 and hα3β4 AChRs 10, 11 . However, we do not have experimental evidence of the exact location and structural components of the mecamylamine binding sites at other members of the AChR family and a clear understanding of its inhibitory mechanism(s). To determine whether (±)-mecamylamine inhibits muscle AChRs by a competitive and/or noncompetitive mechanism(s), Ca 2+ influx and radioligand competition Mecamylamine inhibits muscle nicotinic acetylcholine receptors by competitive and noncompetitive mechanisms , we can manipulate the different receptor conformational states in a variety of in vitro assays [13] [14] [15] [16] [17] and the binding site location for phencyclidine hydrochloride (PCP)/TCP has already been characterised in muscle AChRs 13, 15, 18 . Finally, molecular docking studies are performed to determine the molecular orientation of each isomer and the most important structural components in the binding pockets using the Torpedo AChR model in the open and closed states 17, 18 . Although this study does not intend to determine the therapeutic properties of mecamylamine enantiomers, the results from this work will pave the way for a better understanding of how each enantiomer interacts with different AChR binding domains in distinct conformational states. The subsequent use of this knowledge at neuronal AChRs will be fundamental for the development of novel mecamylamine derivatives with antidepressant, antiaddictive and pro-cognitive properties for therapeutic purposes. 
Materials and methods

Materials
Ca
2+ influx measurements in TE671-hα1β1γδ and HAM293-hα1β1εδ cell lines Cell culturing and Ca 2+ influx assays were carried out as previously described 14, 15, 17 .
Briefly, TE671-hα1β1γδ and HAM293-hα1β1εδ cells were seeded in Dulbecco's modified Eagle medium/10% FBS medium 48 hours prior to the experiment on black 96-well plates ( Costar, New York, USA) at a density of 4 × 10 4 per well and incubated at 37°C in a humidified atmosphere (5% CO 2 /95% air). On the day of the experiment, the medium was removed by flicking the plates and replaced with 100 µL Dulbecco's modified Eagle Medium/10% FBS containing 2 μM Fluo-4 (Molecular Probes, Eugene, OR, USA) in the presence of 2.5 mM probenecid (Sigma, Buchs, Switzerland). The cells were then incubated at 37°C in a humidified atmosphere (5% CO 2 /95% air) for 1 hour. Plates were flicked to remove excess Fluo-4, washed once with N-methyl-D-glucamine (NMDG)/ HEPES-buffered salt solution (130 mM NMDG, 4.5 mM KCl, 2 mM CaCl 2 , 0.8 mM MgSO 4 , 0.9 mM KH 2 PO 4 , 25 mM glucose, 20 mM HEPES, pH 7.4), refilled with 100 µL of NMDG-HEPES-buffered salt solution containing different concentrations of (±)-mecamylamine, preincubated for 5 minutes and then placed in the cell plate stage of the fluorimetric imaging plate reader (Molecular Devices, Sunnyvale, CA, USA). A baseline consisting of five measurements of 0.4 seconds each was recorded. (±)-Epibatidine (1 µM) was then added from the agonist plate to the cell plate using the 96-tip pipettor simultaneously to fluorescence recordings for a total length of 3 minutes. The laser excitation and emission wavelengths were 488 and 510 nm, at 1 W, with a CCD camera opening of 0.4 seconds. 18, 24 were used as docking targets. Mecamylamine enantiomers, TCP and (-)-cytisine, in the neutral and protonated states, were sketched and optimised using HyperChem 6.03 ( HyperCube Inc., Gainesville, FL, USA) as previously described 10, 11, 16 . AutoDock Vina 25 was used for docking simulations of flexible ligands into the rigid target (whole AChR model), generating a series of docking poses and their respective estimated free energies of binding. The lower energy conformations were selected from each cluster of superposed poses. The parameters used are those described previously 26 .
To investigate the stability of the best scored complexes, 10-nanosecond molecular dynamics simulations were subsequently performed (see Supplementary Material).
Results
Inhibition of (±)-epibatidinemediated Ca
2+ influx in human muscle AChRs by (±)-mecamylamine The Ca 2+ influx results indicate that (±)-mecamylamine inhibits (±)-epibatidine-induced AChR activation in TE671-hα1β1γδ ( Figure 2A ) and HAM293-hα1β1εδ ( Figure 2B ) cells. The calculated IC 50 values are similar for both AChR subtypes using either the preincubation or co-injection condition (Table 2) . Nevertheless, the inhibitory potencies increase 5-7 times using the co-injection protocol. The calculated n H values for (±)-mecamylamine are close to unity ( Table 2 ), indicating that the inhibition elicited by this compound is produced by a noncooperative mechanism.
(±)-Mecamylamine inhibits Torpedo AChRs by competitive and noncompetitive mechanisms
The effect of (±)-mecamylamine on [ is evident that (±)-mecamylamine displays nine-fold higher affinity for the resting AChR compared to that of the desensitised AChR ( Table 1 Figure 4A shows that (±)-mecamylamine does not enhance [ 3 H]cytisine binding to resting (but activatable) AChRs but inhibits it (although not totally), opposite to that observed for other noncompetitive antagonists (NCAs) 14, 16 . The observed n H value in the desensitised state is close to unity (Table 1) , suggesting a noncooperative interaction, whereas an apparent n H value of 0.53 was determined in the resting AChR, suggesting a negative cooperative interaction. Using a two-site model, a better correlation value (r 2 = 0.92) was obtained showing two binding populations. In this regard, (±)-mecamylamine binds to the agonist sites of resting AChRs with higher affinity compared to that in the desensitised state (Table 1) . There are two main potential explanations for the observed pharmacological behaviour in the resting AChR: (1) (±)-mecamylamine displaces [ 3 H]cytisine from other allosteric sites. This possibility is supported by the docking results (see sections below), and (2) (±)-mecamylamine binds to the resting and desensitised AChRs observed in native membranes (i.e. ~80% resting and ~20% desensitised AChRs) 27 with different affinities. In this regard, the largest population (72%; Figure 4A ) corresponds to that with the highest binding affinity (1.46 ± 0.21 µM), whereas the smallest population presents very low binding affinity (>3 mM) ( Table 1 ). This latter population could be alternatively AChRs with potency EC 50 = 0.26 ± 0.04 (n = 27) and 0.64 ± 0.06 µM (n = 13), respectively. Subsequently, cells were pretreated with several concentrations of (±)-mecamylamine followed by addition of 1 μM (±)-epibatidine (○). Alternatively, (±)-mecamylamine and (±)-epibatidine were co-injected together (�).
Response was normalised to the maximal (±)-epibatidine response which was set as 100%. The plots are representative of three determinations, respectively, where the error bars correspond to the SD. The calculated IC 50 and n H values are summarised in Table 2 . Figure 4B) . The results clearly demonstrate that (±)-mecamylamine does not interact with the agonist binding sites of neuronal AChRs, even at the highest concentrations used (i.e. 1 mM).
found for the resting and desensitised states with r 2 values of 0.84 ( Figure 5B ) and 0.96 ( Figure 5D ), respectively. This suggests that (±)-mecamylamine inhibits [ 3 H]TCP binding to either the resting or desensitised AChR by a steric mechanism, or in other words that (±)-mecamylamine and PCP bind to overlapping sites.
Molecular docking of mecamylamine enantiomers, TCP and (-)-cytisine to the open and closed
AChRs Each ligand, in the neutral and protonated state, was docked into Torpedo AChRs in the closed ( Figure 6 ) and open ( Figure 7) states. Since similar results were observed for either mecamylamine enantiomer (see Table 3 ), only the results for (S)-(+)-mecamylamine are shown. The docking results indicate that mecamylamine enantiomers interact with luminal and nonluminal (NL) sites located at the transmembrane domain (TMD) of the receptor, as well as with orthosteric (ORT) and allosteric (A) sites located at the extracellular domain. Since mecamylamine is 100% protonated at physiological pH 10, 11 , the different modes of binding are shown only for the protonated state. Since the same results were observed for the neutral form, the corresponding docking results are not shown. However, there is one important difference, (S)-(+)-, but not (R)-(-)-mecamylamine, binds to NL6 in the open AChR model (see Table 3 ).
In the closed Torpedo AChR, both TCP and (S)-(+)-mecamylamine bind to a luminal domain located between the valine (position 13') and leucine (position 9') rings ( Figure 6A and B) . More specifically, the ligands interact by van der Waals contacts with nonpolar residues from the valine (i.e. , and increasing concentrations of (±)-mecamylamine. Nonspecific binding was determined at 1 mM CCh. Each plot is the combination of at least three separated experiments each one performed in triplicate, where the error bars correspond to the SD values. In the absence of any ligand (○), the best nonlinear fitting (r 2 = 0.92) was found using the two sites model, where the largest population (72%) corresponds to that with the highest binding affinity. The fitting using the one site model and a theoretical n H = 1 is also shown (---) for comparative purposes. The obtained IC 50 values were transformed into K i values using Eq (1), and the K i and n H values were summarised in Table 1 sites ( Figure 6C-F) , where two of them ( Figure 6C and D) overlap the NL sites for TCP (see NL1 and NL2 in Table 3 ). The NL1 site is located at the boundary of the α1-and γ-TMDs, including α1-M1 (i.e. Pro-221, Ile-220 and Leu-224), γ-M2 (i.e. Leu-265 and Phe-266) and γ-M3 (i.e. Ser-293, Leu-294 and Val-297) ( Figure 6C ; Table 3 ). Although γ-Leu-265 and γ-Phe-266 are located at M2, they are oriented towards γ-M3 and α1-M3, respectively. The NL2 site is located in a pocket within the α1 subunit formed by M1 (i.e. Phe-214, Val-215, Val-218 and Ile-219) and M3 (i.e. Tyr-277, Met-278 and Phe-280) ( Figure 6D ; Table 3 ). Two additional NL sites, NL3 and NL4, were observed for (S)-(+)-mecamylamine. The NL3 site is located at the boundary of the α1 and γ TMDs, including γ-M1 (i.e. Asn-224 and Leu-231), γ-M2 (i.e. Leu-257, Leu-258 and Val-261) and α1-M3 (i.e. Val-285 and Ile-286) ( Figure 6E ; Table 3 ). Although γ-Leu-257, γ-Leu-258 and γ-Val-261 are located at M2, γ-Leu-257 and γ-Val-261 are oriented towards α1-M3 and γ-Leu-258 towards γ-M1. (S)-(+)-Mecamylamine interacts by van der Waals contacts with nonpolar residues, including Leu-231, Leu-257, Leu-258, Leu-261, Val-285 and Ile-286. In addition, the amino group of (S)-(+)-mecamylamine forms a hydrogen bond with the carbonyl oxygen of γ-Asn-224. The NL4 site is located at the extracellulartransmembrane junction from the β1 subunit ( Figure 6F ). In this domain, (S)-(+)-mecamylamine interacts by van der Waals contacts with the aromatic residues Phe-135 (located at the extracellular domain) and Tyr-283 (at M3), the nonpolar residue Leu-284 (at M3), the aliphatic portion of Ser-274 (at M2) and with Ile-279 (at the M2-M3 segment). Although initial docking results suggested that (-)-cytisine overlaps the NL1 and NL3 sites, moleular dynamics (MD) results indicate that these interactions are unstable (see Figure  S1F , Supplementary Material) and thus, they are not included in the docking results.
Although the results in the open state are similar to that found in the closed state ( Figure 6A ), some differences were observed ( Figure 7A ). An important difference is that in the open state TCP and (S)-(+)-mecamylamine additionally interacts with δ-Cys-262 located at the serine ring (position 6'). In addition, the different orientation of the amino group of (S)-(+)-mecamylamine in the NL3 site ( Figure 7D ) precludes the formation of the hydrogen bond observed in the closed state ( Figure 6E ). Amongst similitude, we can indicate that TCP and (S)-(+)-mecamylamine bind to the same luminal ( Figure 7B ), NL1 (at the boundary of the α1-and γ-TMDs; not shown) and NL2 ( Figure 7C ) sites, although with different orientations as that described for the closed AChR model ( Figure 6B , C and D, respectively; Table 3 ). More specifically, TCP interacts by van der Waals contacts with nonpolar residues at M1 (i.e. Phe-214 and Val-215), M3 (i.e. Tyr-277 and Phe-280) and M4 (i.e. Ile-431) ( Figure 7C) . In the open state, TCP binds to additional NL sites, including NL3, NL4 and NL5. In the NL3 site, TCP interacts with the same residues as that for (S)-(+)-mecamylamine in the open state ( Figure 7D ; Table 3 ). In the NL4 site, the interacting residues (within the β1 subunit) for TCP (within the δ subunit) is located at the M1 (i.e. Lys-224 and Tyr-228), M2 (i.e. Val-285), M2-M3 (i.e. Leu-287) and extracellular (i.e. Phe-137) segments ( Figure 7F ).
On the other hand, (S)-(+)-mecamylamine and (-)-cytisine bind to overlapping sites within the δ subunit (see NL6 in Table 3 ). The ligands interact mainly by van der Waals contacts with nonpolar residues located at M1 (i.e. Phe-247), M3 (i.e. Val-302 and Val-309) and M4 (i.e. Ile-460, Val-464 and Leu-467) ( Figure 7G ). Although initial docking results suggest that (-)-cytisine binds to two sites located at the boundary of the α1-and γ-TMDs from the closed AChR, MD results indicate that these interactions are unstable (see Figure S1F , Supplementary Material), and thus, it is not included in the docking results. (-)-Cytisine also binds to NL7 in the open AChR ( Figure 7H ; Table 3 ). In this site, (-)-cytisine interacts mainly by van der Waals contacts with nonpolar residues at α1-M2 (i.e. Ile-247 and Leu-251), α1-M3 (i.e. Val-293), γ-M1 
Open L β1-V261 (13') δ-V269 (13') α1-L251 (9') β1-L257 (9') γ-L259 (9') δ-L265 (9') δ-C262 (6') Figure S2C , Supplementary Material), and thus this hydrogen bond is not shown in Figure 7H .
The docking results at the extracellular domain indicate that (S)-(+)-mecamylamine overlaps the (-)-cytisine (i.e. ORT) sites at the α1/δ and α1/γ interfaces from the closed ( Figure 6G ) and open AChR models ( Table 3 ). The aromatic portion of (-)-cytisine is stabilised by π-π interactions with γ-Trp-54 ( Figure 6G ) or δ-Trp-57, located at the complementary component.
Although initial docking results suggest the formation of a hydrogen bond between the amino moiety of (S)-(+)-mecamylamine and γ-Trp-54, MD results indicate that this interaction is unstable (see Figure S1E , Supplementary Material), thus this hydrogen bond is not shown in Figure 6G . 
A, allosteric; C, complementary component; L, luminal; NL, nonluminal; ORT, orthosteric; P, principal component; P/N, protonated/neutral state.
α1-Tyr-198, α1-Tyr-93 and α1-Trp-149, located at the principal component ( Figure 6G ). (S)-(+)-Mecamylamine and (-)-cytisine also bind to several A sites. In the A1 site, located close to the extracellulartransmembrane junction from the α1 subunit, both molecules interact mainly by van der Waals contacts with Leu-40, Val-50, Trp-176 and Phe-205 ( Figure 6H ; Table 3 ). In the A2 site, only (-)-cytisine is stabilised within the β1 subunit by π-π interactions with His-160 and Phe-209, and additional van der Waals interactions with Lys-191 and Leu-35 ( Figure 7I ; Table 3 ). Although initial docking results suggest the existence of an additional A site for (-)-cytisine, MD results indicate that this interaction is unstable (see Figure S1D , Supplementary Material), thus this locus is not included in Figure 7A .
Comparison of the estimated free energy of binding values suggests that both mecamylamine enantiomers bind to the luminal site at the closed AChR with slightly lower energies of binding compared to that for the open state (Table 3 ). In general, TCP has more favourable energy of binding than that for the mecamylamine enantiomers. The energies of binding for (-)-cytisine at the ORT sites are more favourable than that for the mecamylamine enantiomers.
Ligand
AChR state 
Bind
Discussion
Although (±)-mecamylamine inhibits several AChR subtypes (see Introduction), we do not have experimental evidence of the exact location and structural components of the mecamylamine binding sites and a clear understanding of its inhibitory mechanism(s). The main goal of this study was to functionally and structurally characterise the binding sites and inhibitory mechanisms elicited by (±)-mecamylamine on muscle-type AChRs.
The Ca
2+
influx results indicate that the inhibitory potency of (±)-mecamylamine is increased 5-7 times when the human embryonic and adult muscle AChRs are activated by (±)-epibatidine in the presence of (±)-mecamylamine (co-injection protocol) compared to that obtained after (±)-mecamylamine pretreatment (Table 2 ). Based on these results, (±)-mecamylamine binds better to the recently activated AChR, and consequently it might inhibit ion flux by maintaining the receptor in this blockade state for longer time (decreasing the fraction of activated ion channels), or alternatively by inducing receptor desensitisation. The former possibility is consistent with the trapping blocking mechanism described for (±)-mecamylamine in different AChR subtypes 8, 9 , whereas the latter possibility is ruled out based on the fact that (±)-mecamylamine does not increase [ Figure 4A ), opposite to that observed for other desensitising NCAs 14, 16 . [ 3 H]TCP competition results support the view that (±)-mecamylamine binds to the TCP sites at the resting AChR with nine-fold higher affinity than that for the desensitised AChR (Table 1 ). In general, NCAs present higher affinity when the AChR is in the desensitised state, and only few compounds (e.g. barbiturates, [3-(trifluoromethyl (Figure 5 ). Docking results on the closed and open AChR states also support the view that both mecamylamine enantiomers and TCP interact with a luminal binding site located between the valine (position 13') and leucine (position 9') rings ( Figures 6A-6B and 7A-7B) . Interestingly, this domain is extended to the serine ring (position 6') in the open AChR. The same binding site location was observed for other NCAs [13] [14] [15] [16] [17] . The determined luminal binding site is supported by the voltage-dependent inhibition elicited by (±)-mecamylamine 8, 9 , and by single mutation studies at α3β4 AChRs, indicating that its effect was increased by the double 6′ 10′ mutation and this effect was greater than that produced by each single mutant 28 . Although in principle (±)-mecamylamine is considered an open-channel blocker (see 4 and references therein), additional results indicate that its pharmacological activity is more complex than previously thought 3, 5, 8, 9, 29 . For example, previous results indicating that the inhibitory action mediated by (±)-mecamylamine in parasympathetic ganglia (i.e. α3β4 AChRs) is decreased at higher agonist concentrations 3 and that nicotine agonists inhibited [ (Table 1) , it practically does not interact with the neuronal AChR agonist sites (Figure 4 ). In addition, docking results support the view that mecamylamine enantiomers overlap the ORT binding sites (i.e. α1/γ and α1/δ subunits) in both AChR models (see Figure 6G) . Based on the crystal structure of the (-)-cytisine-AChBP complex (PDB id: 4AFO), the binding site is formed by residues from the principal (i.e. Tyr-91, Trp-145, Tyr-186, Tyr-193, Cys-188 and Cys-189) and complementary (i.e. Tyr-53, Met-114 and Ile-116) components, respectively 31 . Molecular docking of (-)-cytisine at α4β2 AChRs also shows residues α4-Trp-147, α4-Tyr-195, α4-Tyr-91 and β2-Trp55 forming its binding site 32 . The residues from both studies correspond very well with our docking results for (-)-cytisine and mecamylamine enantiomers (i.e. α1-Tyr-93, α1-Trp-149, α1-Tyr-190 and α1-Tyr-198 at the principal component, and γ-Trp-54/δ-Trp-57 at the complementary component) (see Figure 6G ). Our results suggest that (±)-mecamylamine may bind to ORT and luminal sites at muscle AChRs.
The docking results also show several NL binding sites for mecamylamine enantiomers and TCP at each AChR model (Table 3) . Interestingly, several of the docked NL sites coincide with the general anaesthetic binding domains found in the proton-activated ion channel (GLIC) from the bacteria Gleobacter violaceus 33 and α4β2 AChRs
34
. Different general anaesthetics bind to intrasubunit and intersubunit pockets along the TMD. In particular, desflurane and propofol interact with an intrasubunit pocket formed by residues GLIC-Ile-201 (corresponding to α1-Val-218 at the NL2 site), GLICIle-202 (corresponding to α1-Ile-219 at the NL2 site), GLIC-Tyr-254 (corresponding to α1-Tyr-277/β1-Tyr-283 at the respective NL2/NL4 site) and GLIC-Thr-255 (corresponding to α1-Met-278/β1-Leu-284 at the respective NL2/NL4 sites) 33 . Halothane and ketamine bind to several pockets 34 , where some of
